Lantheus Merges with Curium in $8 Billion Deal After Dual FDA Approvals

A pending $8.0 billion merger with Curium is reshaping the radiopharmaceutical manufacturing landscape, and Lantheus Holdings' Q3 2026 results, filed alongside two simultaneous FDA approvals, signal the scale of operational integration that plant heads and QA directors will need to prepare for. The combined entity is projected to serve patients across more than 70 countries, spanning both diagnostics and therapeutics.

Under the definitive agreement announced August 3, 2026, Curium US Holdings LLC will acquire all outstanding Lantheus shares at $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights of up to $12.00 per share tied to commercial milestones through 2030. Total per-share consideration reaches up to $114.50. The Lantheus Board of Directors unanimously approved the transaction; Lantheus has suspended full-year 2026 financial guidance and will not host an earnings call pending close.

The regulatory dimension is equally significant. The FDA approved TAUKLARIFY™ (florquinitau F-18 injection), an F-18-labeled tau PET imaging agent for evaluating adults with cognitive impairment being assessed for Alzheimer's disease. Separately, the agency granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), designating it bioequivalent and therapeutically equivalent to LUTATHERA® for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Two approvals in a single quarter, one diagnostic, one therapeutic, underscore the dual-modality manufacturing complexity the merged company will carry forward under GMP requirements.

For QA directors, the BRAVNETSA bioequivalence determination is a notable regulatory precedent in the Lu-177 space, with implications for process validation documentation and comparability protocols under 21 CFR Part 211. Short-lived isotope supply chains, already operationally constrained by decay timelines, will face additional scrutiny as the combined Curium-Lantheus network scales across jurisdictions with differing regulatory frameworks.

Q3 financials reflect a business in transition. Worldwide revenue grew 1.5% year-over-year to $389.9 million, while GAAP net income declined 19.4% to $22.4 million, consistent with merger-related cost absorption. Adjusted net income rose 34.3% to $115.1 million. PYLARIFY sales of $238.9 million declined 0.7%; Neuraceq posted a 123.0% increase to $45.6 million; DEFINITY grew 4.8% to $85.7 million.

The CVR structure, contingent on commercial milestones through 2030, means manufacturing output and regulatory compliance timelines for TAUKLARIFY and BRAVNETSA will carry direct financial consequences for the merged organization well beyond close.

Source: Lantheus Holdings, Inc. via GlobeNewswire, November 5, 2026. No earnings call was held in connection with Q3 2026 results.